Therapeutic Index Improvements of ADCs: What Are the Next Breakthroughs?
Time: 1:20 pm
day: Day Two - PM
Details:
- Discussing the impact of ADC design on anti-tumor activity and platform adverse events
- Clinical liabilities of Exatecan/Top1 based ADCs and mitigation strategies
- Dual payload conjugates: same or better than chemo combos?